Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 12/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PPOX | P50336 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 3/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031365 | 0.87 | EPAS1 (0.37) | EPAS1TDP1MEN1TTRPPOX | |
| SCHEMBL3036533 | 0.83 | MEN1 (0.41) | TDP1MEN1TTRPPOXKMT2A | |
| SCHEMBL3641931 | 0.81 | EPAS1 (0.38) | EPAS1TDP1MEN1TTRPPOX | |
| SCHEMBL13560498 | 0.79 | EPAS1 (0.35) | EPAS1VEGFATBXA2RLMNA | |
| SCHEMBL3031375 | 0.77 | EPAS1 (0.40) | EPAS1TDP1MEN1KMT2AVEGFA | |
| SCHEMBL3028132 | 0.76 | EPAS1 (0.38) | EPAS1MEN1KMT2AVEGFALMNA | |
| SCHEMBL3023944 | 0.75 | PIN1 (0.40) | MEN1KMT2ALMNA | |
| SCHEMBL3038920 | 0.75 | CYP1A2 (0.41) | EPAS1TDP1MEN1TTRPPOX | |
| SCHEMBL4752770 | 0.75 | CYP1A2 (0.41) | EPAS1TDP1MEN1TTRPPOX | |
| SCHEMBL3641926 | 0.75 | EPAS1 (0.36) | EPAS1TDP1MEN1TTRPPOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304419-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100216746-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216746-A1 | CHEMICAL COMPOUNDS | SAMHD1, POLRMT, NUDT1 | EPAS1 3652/4885TDP1 243/4885MEN1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.